Christopher Morabito

Christopher Morabito

Company: Astria Therapeutics

Job title: Chief Medical Officer

Seminars:

Track Chair: 10:13 am

Read more

day: Day Two Discovery Track AM

STAR-0310: A Monoclonal Antibody OX40 Antagonist 12:15 pm

OX40 inhibition is a clinically validated mechanism for the treatment of AD Using half-life extension technology with the aim of durable efficacy with less frequent dosing every 2-3 months, STAR0310 is designed with the potential to be a first-choice treatment that reduces disease and treatment burden to help normalize the lives of people with atopic dermatitis STAR-0310 has a…Read more

day: Day One Discovery Track AM

Bridging the Gap: Translating Candidates to the Clinic for Chronic Disease
10:15 am

Read more

day: Day Two Discovery Track AM

A Hanson Wade Group Company

© Copyright 2024 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.